Silver nasal sprays: Misleading Internet marketing

Ear, Nose and Throat Journal

Volumn 87, Issue 4, 2008, Pages

  Gaslin, Michael T ^a   Rubin, Cory ^a   Pribitkin, Edmund A ^a,b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOSE DROPS; NOSE SPRAY; SILVER; SILVER ARSPHENAMINE; SILVER DERIVATIVE; SILVER NITRATE; SULFADIAZINE SILVER;

ANTIMICROBIAL ACTIVITY; ARGYRIA; COLLOID; DRUG FORMULATION; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; HERBAL MEDICINE; HUMAN; INTERNET; LONG TERM CARE; MARKETING; MEDICAL INFORMATION; MEDICAL SPECIALIST; OCCUPATIONAL SAFETY; PATIENT EDUCATION; QUALITY CONTROL; RECOMMENDED DRUG DOSE; REVIEW; SEARCH ENGINE; SYPHILIS; ARTICLE; DRUG CONTROL; INTRANASAL DRUG ADMINISTRATION; LEGAL ASPECT; SOLUTION AND SOLUBILITY; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, TOPICAL; ARGYRIA; DRUG AND NARCOTIC CONTROL; HUMANS; INTERNET; MARKETING; SILVER COMPOUNDS; SOLUTIONS; UNITED STATES;

EID: 45549091998     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130808700414     Document Type: Review

References (20)

1. Hill WR, Pillsbury DM. Argyria: The Pharmacology of Silver. 1st ed. Baltimore:TheWilliams and Wilkins Co., 1939.
2. Frommann C. Ein Fall von Argyria mit Silberabscheidungen im Darm, Leber, Nieren und Milz. Virch Arch Bd 1859:135-47.
3. Sataline L. Tarnished silver. Lancet 2004; 363 9415:1166.
4. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule. Fed Regist 1999; 64 158:44653-8.
5. Tomi NS, Kränke B, Aberer W. A silver man. Lancet 2004; 363 9408:532.
6. Bouts BA. Images in clinical medicine: Argyria. N Engl J Med. 1999; 340 20:1554.
7. Bianchi L, Orlandi A, Di Stefani A, et al. "Familial" generalized argyria. Arch Dermatol 2006; 142 6:789-90.
8. Wickless SC, Shwayder TA. Medical mystery - the answer. N Engl J Med. 2004; 351 22:2349-50.
9. White JM, Powell AM, Brady K, Russell-Jones R. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin Exp Dermatol 2003; 28:254-6.
10. Brandt D, Park B, Hoang M, Jacobe HT. Argyria secondary to ingestion of homemade silver solution. J Am Acad Dermatol 2005; 53 (2 Suppl 1): S105-107.
11. McKenna JK, Hull CM, Zone JJ. Argyria associated with colloidal silver supplementation. Int J Dermatol 2003; 42 7:549.
12. Wadhera A, Fung M. Systemic argyria associated with ingestion of colloidal silver. Dermatol Online J 2005; 11 1:12.
13. Fung MC, Bowen DL. Silver products for medical indications: Risk-benefit assessment. J Toxicol Clin Toxicol 1996; 34 1:119-26.
14. van Hasselt P, Gashe BA, Ahmad J. Colloidal silver as an antimicrobial agent: Fact or fiction? J Wound Care 2004; 13 (4): 154-5.
15. Bleehen SS, Gould DJ, Harrington CI, et al. Occupational argyria: Light and electron microscopic studies and X-ray microanalysis. Br J Dermatol 1981; 104 1:19-26.
16. Massi D, Santucci M. Human generalized argyria: A submicroscopic and X-ray spectroscopic study. Ultrastruct Pathol 1998; 22 (1): 47-53.
17. Gaul LE, Staud AH. Clinical spectroscopy. Seventy cases of generalized argyrosis following organic and colloidal silver medication. JAMA 1935; 104:1387-90.
18. Drake PL, Hazelwood KJ. Exposure-related health effects of silver and silver compounds: A review. Ann Occup Hyg 2005; 49 7:575-85.
19. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290 11:1505-9.
20. Ashar BH, Miller RG, Getz KJ, Pichard CP. A critical evaluation of Internet marketing of products that contain ephedra. Mayo Clin Proc 2003; 78 8:944-6.